• MBX Biosciences

  Participated · Series A · Jul 2020

  MBX Biosciences develops precision-engineered peptide therapies via its proprietary Precision Endocrine Peptide™ (PEP™) platform designed to extend time-action profiles, provide consistent tissue exposure, and enable less frequent dosing. Its lead candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in a Phase 2 trial for chronic hypoparathyroidism, with topline results expected in the third quarter of 2025. MBX 1416, aimed at post-bariatric hypoglycemia, is in a Phase 1 single- and multiple-ascending dose trial with topline data expected in the fourth quarter of 2024. The company also advances an obesity portfolio including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug in IND-enabling studies, plus multiple discovery and preclinical candidates. MBX says proceeds from its recent financing will support operations into 2026 and fund progression of its clinical and early-stage programs. The company is based in Carmel, Indiana. MBX Biosciences is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide (PEP) therapeutic candidates for endocrine disorders. Its lead candidate, MBX 2109, is a long-acting parathyroid hormone peptide prodrug designed for once-weekly dosing and is in a Phase 1 trial for hypoparathyroidism; MBX 2109 received FDA Orphan Drug designation in July 2022. Proceeds from the financing will support continued clinical advancement of MBX 2109, the preclinical program MBX 1416, and discovery programs in endocrine diseases. The company positions its PEP platform to overcome limitations of traditional peptide therapeutics by delivering sustained activity and improved pharmaceutical properties. MBX says its goal is to simplify disease management and improve outcomes and quality of life for patients with endocrine disorders. MBX is based in Carmel, Indiana. MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases with a focus on peptide therapeutics. The company advances a preclinical pipeline of peptide candidates directed at clinically validated molecular targets. MBX's platform and drug candidates are built on medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, who is co-founder and chief scientific officer. The company intends to advance its candidates toward clinical investigation to address endocrine disorders with substantial unmet medical need. MBX's leadership team, including president and CEO Kent Hawryluk, previously collaborated on successful endocrine drugs such as Humalog and Forteo. The company is based in Carmel, Indiana and is supported by leading life-science investors including Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates. MBX Biosciences develops therapeutics aimed at rare endocrine disorders that the company says represent substantial unmet medical need. The company is pursuing initial discovery research to identify drug candidates with potential life‑saving properties against these disorders. MBX was founded by Indiana University Bloomington Distinguished Professor Richard DiMarchi, IUPUI alumnus Kent Hawryluk, and Tim Knickerbocker, and maintains several ties with Indiana University. The startup has an agreement to support research at the DiMarchi Laboratory in Bloomington and is a sponsor of IU‑based research. MBX completed an initial $2.5 million financing to fund its early discovery work. The leadership team has prior experience pairing on Marcadia Biotech and MB2, both acquired by large pharma, which the company cites as part of its institutional expertise.

• SharpenCX

  Participated · Equity · Mar 2019

  SharpenCX provides a unified, all-in-one contact center platform built with an agent-first design, cloud-native architecture, and a holistic AI environment. The platform offers a simple omnichannel agent interface, advanced analytics and reporting, and configurable agent experiences designed for easy implementation and immediate ROI. SharpenCX emphasizes empowering agents to deliver better customer interactions and positions its product as a next-gen CCaaS/UCaaS solution. The company was founded in 2011 and says the new investment will accelerate product innovation and continue its focus on serving customers. The announcement does not disclose operating metrics such as revenue or user counts. Sharpen Technologies is an Indianapolis, IN-based provider of an agent-first omnichannel cloud contact center platform. Led by CEO Bill Gildea, the platform enables agents to work from anywhere with a PC, headphones, and an internet connection. The software consolidates calls, texts, webchats, emails, and social media into real-time, single interactions so agents can move seamlessly between channels. The company said it will use the funds to expand operations and broaden its business reach. The article does not disclose operating metrics such as revenue or user counts. The report frames the product as a work-from-anywhere solution for contact center agents. Sharpen Technologies develops an agent-first omnichannel cloud contact center platform that lets users work-from-anywhere and handle calls, texts, webchats, emails, social media, and video in real time within a single interaction. The product emphasizes agent experience with out-of-the-box integrations, reporting and analytics, and has been recognized for dramatic ROI by Frost & Sullivan and rated highly by Nemertes Research. The company reported a 236% increase in new bookings in 1H 2020 versus 1H 2019 and a 137% growth rate over the last three years, earning a spot on the 2020 Inc. 5000 list. Sharpen has raised more than $40 million to date and announced a $12 million growth funding round to fuel continued expansion. Management says the round will support continued innovation on its agent-first platform and maintain a high-touch service model. Sharpen positions itself to capture increased cloud contact center adoption as Gartner notes limited pre-pandemic cloud transition and rising work-from-home trends in CX workforces. Sharpen Technologies offers a cloud-native, agent-first omni-channel contact center platform that gives agents a single interface to manage communications across multiple channels. Its proprietary Agent Experience Score (AXS) measures agent performance and well-being. The platform promises financially backed 99.999 percent uptime and addresses long-standing agent issues that degrade customer experience. Sharpen markets a full-featured solution aimed at improving customer service and scalability for contact centers. The company plans to use new capital to grow its sales team, extend market reach, and expand the product platform. In 2018 Sharpen reported strong operating momentum: new contract dollar amount rose 700 percent, booked annual recurring revenue grew 150 percent year-over-year, and contact center customer count increased 80 percent versus 2017.

No current team members are available.